Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001193125-26-161582
Filing Date
2026-04-17
Accepted
2026-04-17 16:17:51
Documents
13

Document Format Files

Seq Description Document Type Size
1 424B5 d106297d424b5.htm 424B5 427888
2 EX-FILING FEES d106297dexfilingfees.htm   iXBRL EX-FILING FEES 19085
3 GRAPHIC g106297g03a45.jpg GRAPHIC 55661
4 GRAPHIC g106297g16a16.jpg GRAPHIC 50358
  Complete submission text file 0001193125-26-161582.txt   702074

Data Files

Seq Description Document Type Size
17 EXTRACTED XBRL INSTANCE DOCUMENT d106297dexfilingfees_htm.xml XML 5131
Mailing Address 195 CHURCH STREET 16TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 16TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B5 | Act: 33 | File No.: 333-291517 | Film No.: 26871816
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)